Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 41Terminated 12Unknown 7Withdrawn 1Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors 1

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × Zoledronic Acid × Clear all
NCT06221072 2024-01-24

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Shanghai JMT-Bio Inc.

Phase 3 Not yet recruiting
1,360 enrolled

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡